CO6160312A2 - Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico - Google Patents

Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico

Info

Publication number
CO6160312A2
CO6160312A2 CO09041752A CO09041752A CO6160312A2 CO 6160312 A2 CO6160312 A2 CO 6160312A2 CO 09041752 A CO09041752 A CO 09041752A CO 09041752 A CO09041752 A CO 09041752A CO 6160312 A2 CO6160312 A2 CO 6160312A2
Authority
CO
Colombia
Prior art keywords
alkyl
halogen
optionally substituted
independently selected
substituents independently
Prior art date
Application number
CO09041752A
Other languages
English (en)
Inventor
Ford Rhonan
Andrew Mather
Antonio Mete
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6160312A2 publication Critical patent/CO6160312A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)

Abstract

1.- Un compuesto de la fórmula (I),dondeR1 y R2 junto con el átomo de carbono al cual los dos están directamente unidos forman un anillo carbocíclico alifático de 7 miembros el cual puede ser opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados de halógeno, hidroxil, C1-6 alcoxi, NH2, NH(C1-6 alquil), N(C1-6 alquil)2 y C1-6 alquil, dicho C1-6 alquil puede ser opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados de halógeno e hidroxil; R3 representa fenil o un anillo heteroaril de 5 a 6 miembros, cada uno de los cuales puede ser opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados de halógeno, ciano, nitro, SH, S(O)0-2R9, NR10R11, S(O)2NR12R13, C(O)NR14R15, C(O)2R16, NR17S(O)2R18, NR19C(O)R20, NR21C(O)2R22, NR23C(O)NR24R25, OR26 y C1-6 alquil, dicho C1-6 alquil puede ser opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados de halógeno, hidroxil; C1-6 alcoxi, NH2, NH(C1-6 alquil) y N(C1-6 alquil)2; R4 representa un grupo de la fórmula (II) o (lIla) o (IIIb); donde Y es -CH2-, -CH2CH2- o -CH2CH2CH2- y la sustitución en el anillo en el grupo (II) puede ser en la posición 3 ó 4; a es 1 ó 2; b es 1 ó 2; Z es -CH2-; R5 representa un grupo de la fórmula (IV)donde w es 0 ó 1; R6 representa C1-4 alquileno opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados de halógeno, hidroxil, C1-6 alcoxi, NH2, NH(C1-6 alquil) y N(C1-6 alquil)2;cuando w es 0, y es 0; cuando w es 1, y es 0 ó 1; ...
CO09041752A 2006-11-14 2009-04-24 Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico CO6160312A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86566706P 2006-11-14 2006-11-14
US86938406P 2006-12-11 2006-12-11

Publications (1)

Publication Number Publication Date
CO6160312A2 true CO6160312A2 (es) 2010-05-20

Family

ID=39048793

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09041752A CO6160312A2 (es) 2006-11-14 2009-04-24 Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico

Country Status (30)

Country Link
US (2) US8207193B2 (es)
EP (2) EP2256117A1 (es)
JP (1) JP4904402B2 (es)
KR (1) KR20090078828A (es)
AR (1) AR063804A1 (es)
AT (1) ATE496916T1 (es)
AU (1) AU2007321019B2 (es)
BR (1) BRPI0718750A2 (es)
CA (1) CA2669326A1 (es)
CL (1) CL2007003260A1 (es)
CO (1) CO6160312A2 (es)
CY (1) CY1111351T1 (es)
DE (1) DE602007012300D1 (es)
DK (1) DK2094694T3 (es)
EC (1) ECSP099338A (es)
HK (1) HK1134091A1 (es)
HR (1) HRP20110178T1 (es)
IL (1) IL198314A (es)
MX (1) MX2009004780A (es)
MY (1) MY148392A (es)
NO (1) NO20092224L (es)
NZ (1) NZ576679A (es)
PE (1) PE20081164A1 (es)
PL (1) PL2094694T3 (es)
PT (1) PT2094694E (es)
RS (1) RS51650B (es)
RU (1) RU2456286C2 (es)
SA (1) SA07280616B1 (es)
TW (1) TW200825084A (es)
WO (1) WO2008059245A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438915A1 (en) * 2006-07-21 2012-04-11 Mars Incorporated Improvement of arginase levels/activity
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CN102908624A (zh) * 2008-05-13 2013-02-06 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
CN102089304A (zh) * 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
UY31920A (es) * 2008-06-20 2010-01-29 Astrazeneca Ab Nueva combinacion-408
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
BRPI1012980A2 (pt) * 2009-05-19 2016-03-29 Vivia Biotech Sl dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas
KR20130111968A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
EP3373006A1 (en) 2012-04-30 2018-09-12 Biothera, Inc. Beta-glucan immunotherapeutic methods
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) * 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (es) * 1942-12-16
DE2104179C3 (de) 1971-01-29 1980-10-02 Knoll Ag, 6700 Ludwigshafen exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en) 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en) 1972-01-25 1973-09-07 Synthelabo Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en) 1972-12-01 1974-06-28 Synthelabo 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IL77458A (en) 1985-01-14 1990-07-26 Eisai Co Ltd Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
EP0528026A1 (en) 1991-03-07 1993-02-24 G.D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
CA2261692A1 (en) 1996-07-29 1998-02-05 Rolf Johansson Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PT937041E (pt) 1996-11-11 2003-09-30 Christian R Noe Utilizacao de um sal farmaceuticamente aceitavel de (3r,2'r)-3-¬(ciclopentil-hidroxifenilacetil)oxi|-1,1-dimetil-pirrolidinio para a preparacao de um medicamento
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
SK8002003A3 (en) * 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
EP1383730A2 (en) * 2001-04-03 2004-01-28 Aryx Therapeutics Anticholinergic compounds and methods of use
EP2039700A2 (en) 2001-04-30 2009-03-25 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
EA200500618A1 (ru) 2002-10-11 2005-12-29 Пфайзер Инк. Производные индола в качестве бета-2 агонистов
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
CN100450488C (zh) 2003-11-03 2009-01-14 诺顿·希尔思凯尔有限公司 用于干粉吸入剂的软类固醇组合物
WO2006025324A1 (ja) 2004-08-30 2006-03-09 Ono Pharmaceutical Co., Ltd. トロパン化合物およびそれらを有効成分として含有する医薬組成物
EP1797040A1 (en) 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090093485A1 (en) 2004-10-29 2009-04-09 Astrazeneca Ab Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
TW200722418A (en) 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
BRPI0613925A2 (pt) 2005-08-01 2011-02-15 Astrazeneca Ab novos compostos
TW200738635A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
EP1971572A1 (en) 2005-12-16 2008-09-24 Argenta Discovery Limited Cyclic amine derivatives and their uses
EP2013172A4 (en) 2006-04-24 2010-08-04 Astrazeneca Ab NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE
AU2007275931B2 (en) 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
WO2008023157A1 (en) 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
WO2008075006A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
JP4604129B2 (ja) 2006-12-19 2010-12-22 アストラゼネカ・アクチエボラーグ ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096094A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
NZ578475A (en) 2007-02-07 2011-05-27 Pulmagen Therapeutics Synergy Napadisylate salt of a muscarinic m3 antagonist
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702414D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702382D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
CA2676581A1 (en) 2007-02-15 2008-08-21 Argenta Discovery Limited Heterocyclic derivatives as m3 muscarinic receptors
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2008149053A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Ltd. Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
WO2009098453A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
PL2242759T3 (pl) 2008-02-06 2013-06-28 Astrazeneca Ab Związki
WO2009098455A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
GB0808709D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
CN102908624A (zh) * 2008-05-13 2013-02-06 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
GB0808707D0 (en) 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
CN102089304A (zh) * 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2009153536A1 (en) 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
GB0811100D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010018352A1 (en) 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
KR20110045053A (ko) 2008-08-12 2011-05-03 아스트라제네카 아베 2-히드록시-에탄술포네이트 염
GB0814729D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Also Published As

Publication number Publication date
PL2094694T3 (pl) 2011-05-31
HRP20110178T1 (hr) 2011-04-30
US20130005695A1 (en) 2013-01-03
BRPI0718750A2 (pt) 2013-12-03
NO20092224L (no) 2009-06-22
KR20090078828A (ko) 2009-07-20
IL198314A0 (en) 2010-02-17
AU2007321019B2 (en) 2011-04-21
CA2669326A1 (en) 2008-05-22
EP2094694B1 (en) 2011-01-26
AR063804A1 (es) 2009-02-18
US8207193B2 (en) 2012-06-26
WO2008059245A1 (en) 2008-05-22
JP4904402B2 (ja) 2012-03-28
ECSP099338A (es) 2009-06-30
PT2094694E (pt) 2011-03-17
RS51650B (en) 2011-10-31
MX2009004780A (es) 2009-05-21
DE602007012300D1 (de) 2011-03-10
EP2094694A1 (en) 2009-09-02
CL2007003260A1 (es) 2008-05-23
SA07280616B1 (ar) 2010-11-22
AU2007321019A1 (en) 2008-05-22
JP2010509391A (ja) 2010-03-25
DK2094694T3 (da) 2011-04-04
RU2456286C2 (ru) 2012-07-20
MY148392A (en) 2013-04-15
EP2256117A1 (en) 2010-12-01
HK1134091A1 (en) 2010-04-16
PE20081164A1 (es) 2008-10-31
CY1111351T1 (el) 2015-08-05
TW200825084A (en) 2008-06-16
US20100029713A1 (en) 2010-02-04
RU2009115829A (ru) 2010-12-20
IL198314A (en) 2013-06-27
NZ576679A (en) 2011-04-29
ATE496916T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
CO6160312A2 (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico
CO6180439A2 (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR063142A1 (es) Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
DK1755606T4 (da) Quinazolinonderivater, der er anvendelige som vanilloid-antagonister
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
CO5580803A2 (es) Derivados de piperidin-bencensulfonamida
AR057894A1 (es) Derivados de tiofeno
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
SV2006002126A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
EA201390476A1 (ru) Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
CO5631434A2 (es) Derivados de piridina-carboxamida y su uso como plaguicidas
AR055420A1 (es) Derivados de pirimidina sustituidos
AR055666A1 (es) Inhibidores inntr
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
AR059031A1 (es) Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa